PharmAla Signs Advisory Agreement with Mr. Matthew Azrieli
February 06, 2025 16:06 ET
|
PharmAla Biotech
PharmAla adds Matthew Azrieli to Advisory Team
PharmAla Issues Q1 Financial Statements
January 29, 2025 16:10 ET
|
PharmAla Biotech
PharmAla releases its Q1 financial statements
PharmAla Issues Audited Financial Statements, Completes Continuance to Ontario, and Closes Private Placement
December 20, 2024 16:55 ET
|
PharmAla Biotech
PharmAla files audited financials for year ended August 31, 2024, completes continuance and oversubscribed private placement
PharmAla Announces Private Placement
December 13, 2024 09:25 ET
|
PharmAla Biotech
PharmAla announces private placement financing
Psychedelic Science 2025 Conference Announces Workshops, Holiday Sale, and Scholarship Deadline
December 05, 2024 15:44 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
World’s leading psychedelic conference kicks off with workshops from leaders in science, medicine, therapy, policy, Indigenous medicine, and societyUpcoming deadline: speaker submissions, initial...
PharmAla Reaches Agreement in Principle to Supply MDMA to Clinical Trial in Exchange for Full Data License
November 14, 2024 09:20 ET
|
PharmAla Biotech
PharmAla reaches agreement in principle to trade with a clinical trial to trade its LaNeo MDMA for a data license to the trial outcomes.
PharmAla to supply LaNeo MDMA for Clinical Trial at Yale
November 07, 2024 09:20 ET
|
PharmAla Biotech
PharmAla to supply Yale University with MDMA for clinical trial
PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA
October 21, 2024 09:25 ET
|
PharmAla Biotech
PharmAla contracted to sell MDMA to Mt. Sinai Hospital, NY. Terminates Contract with CCrest Labs.
PharmAla Launches MDMA Clinical Trial Tool for Researchers
August 22, 2024 09:07 ET
|
PharmAla Biotech
PharmAla announces the launching of a new tool for clinical researchers, and the appointment of a new CFO effective Oct. 1
Optimi Health Secures Import Permit from Mind Medicine Australia for MDMA and Psilocybin Capsules
May 29, 2024 08:00 ET
|
Optimi Health Corp.
Optimi Health preparing to export 160 doses of MDMA and psilocybin under Australia’s Authorized Prescriber Scheme.